Here are what the editors at HealthDay consider to be the most important developments in Dermatology for August 2012. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Mites, Associated Bacteria Possibly Play Role in Rosacea
THURSDAY, Aug. 30 (HealthDay News) -- A role has been suggested for Demodex mites and their associated bacteria in rosacea, according to a study published online Aug. 29 in the Journal of Medical Microbiology.
Melanoma Risk Declines With Self-Exams Plus Doctor Visit
FRIDAY, Aug. 24 (HealthDay News) -- Risk of deeper melanomas is reduced with self-examination of the skin one to 11 times a year, according to a study published online Aug. 16 in the British Journal of Dermatology.
Metastatic Melanoma Responds to First-Line Interleukin-21
THURSDAY, Aug. 23 (HealthDay News) -- In the first-line treatment of metastatic melanoma, interleukin-21 (IL-21) shows an overall response rate (ORR) of 22.5 percent and warrants further study, according to research published online Aug. 20 in the Journal of Clinical Oncology.
Tattoo Ink Found to Be Source of M. Chelonae Outbreak
WEDNESDAY, Aug. 22 (HealthDay News) -- Premixed tattoo ink has been found to be the source of an outbreak of Mycobacterium chelonae in 19 patients in Rochester, N.Y., according to a study published online Aug. 22 in the New England Journal of Medicine.
At-Home Diode Laser Effective for Permanent Hair Reduction
WEDNESDAY, Aug. 22 (HealthDay News) -- Eight treatments with a home-use diode laser provide effective and safe permanent hair reduction one year after the last treatment, according to research published in the September issue of Lasers in Surgery and Medicine.
Lower MI Risk With TNF Inhibitor Therapy for Psoriasis
WEDNESDAY, Aug. 22 (HealthDay News) -- Patients with psoriasis who are treated with tumor necrosis factor (TNF) inhibitors have a significantly lower risk and incidence of myocardial infarction (MI) compared with those who are treated with topical agents, according to a study published online Aug. 20 in the Archives of Dermatology.
Factors Tied to Photoprotection ID'd for Organ Recipients
TUESDAY, Aug. 21 (HealthDay News) -- For organ transplant recipients, patients factors, including sex and skin type, and receipt of advice from health care providers, are both associated with sun protective behaviors, according to a study published online Aug. 9 in the British Journal of Dermatology.
Azathioprine May Benefit Pediatric Atopic Dermatitis
TUESDAY, Aug. 21 (HealthDay News) -- For pediatric patients with refractory atopic dermatitis (AD), oral azathioprine is associated with clinical improvement, and measurement of thiopurine methyltransferase (TPMT) activity seems useful for monitoring treatment, according to a study published online Aug. 13 in the Journal of the American Academy of Dermatology.
Pathologists Tend to Reclassify Prior Nonmalignant Diagnoses
FRIDAY, Aug. 17 (HealthDay News) -- For dermatopathologists there is a trend toward reclassification of prior nonmalignant diagnoses of severely atypical dysplastic nevi as malignant, according to a study published in the September issue of the Journal of the American Academy of Dermatology.
High-Risk HPV Present in Subset of Penile Carcinomas
MONDAY, Aug. 13 (HealthDay News) -- High-risk human papillomavirus (hrHPV) infection is found in a subset of penile squamous cell carcinomas (PSCCs) that may develop from undifferentiated penile intraepithelial neoplasia (PeIN), according to a study published online Aug. 6 in the Journal of the American Academy of Dermatology.
Prevalence, Risk of Thyroid Disease Up in Vitiligo Patients
MONDAY, Aug. 13 (HealthDay News) -- Both the prevalence and the risk of thyroid diseases are significantly higher among patients with vitiligo compared to those without the condition, according to a study published online Aug. 3 in the British Journal of Dermatology.
Reasons for Discontinuation Vary by Psoriasis Treatment
FRIDAY, Aug. 10 (HealthDay News) -- The reasons for discontinuation of commonly used treatments for psoriasis vary by treatment, according to a study published online July 30 in the Journal of the American Academy of Dermatology.
Topical Treatment Shows Potential for Infantile Eczema
TUESDAY, Aug. 7 (HealthDay News) -- Ten days of treatment with a cream containing 15(R/S)-methyl-lipoxin A4 (LXA4) is well tolerated and reduces the severity of infantile eczema, according to a study published online July 26 in the British Journal of Dermatology.
Photosensitizing Antihypertensive Meds Up Risk of Lip Cancer
TUESDAY, Aug. 7 (HealthDay News) -- For non-Hispanic whites, long-term treatment with photosensitizing antihypertensive agents correlates with an increased likelihood of lip cancer, according to a study published online Aug. 6 in the Archives of Internal Medicine.
Superficial X-Ray Viable for Basal, Squamous Cell Carcinoma
MONDAY, Aug. 6 (HealthDay News) -- Superficial X-ray therapy remains a viable treatment for primary basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) in select patients, according to a study published online July 23 in the Journal of the American Academy of Dermatology.
Spray-Based Therapy Promising for Chronic Venous Leg Ulcers
FRIDAY, Aug. 3 (HealthDay News) -- A spray-based therapy containing growth-arrested allogeneic neonatal keratinocytes and fibroblasts, HP802-247, is associated with a reduction in the wound area of chronic venous leg ulcers, according to a phase 2 study published online Aug. 3 in The Lancet.
Clinicians Can Unintentionally Prompt Nocebo Effect
THURSDAY, Aug. 2 (HealthDay News) -- The nocebo effect, or induction of a symptom perceived as negative by sham treatment and/or the suggestion of negative expectation, may arise from suggestions by doctors and nurses, according to a study published in Deutsches Ärzteblatt International.
Copyright © 2012 ScoutNews, LLC. All rights reserved.
|Previous: August 2012 Briefing - Cardiology||Next: August 2012 Briefing - Diabetes & Endocrinology|
Reader comments on this article are listed below. Review our comments policy.